Brookfield Corp’s CONMED CNMD Stock Holding History

Brookfield Corp’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,598	Closed	-$1.03M	–	681
2022 Q4	$1.03M	Buy	+11,598	New	+$962K	﹤0.01%	495

Other funds holding CNMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Brookfield Corp's CNMD Position: Q1 2023 in Review

Brookfield Corp sold out of CONMED (CNMD) in Q1 2023, closing a stake of 11,598 shares — an estimated $1.03M sold.

Brookfield Corp first reported a position in CNMD in Q4 2022 and held it in 1 quarter. The position peaked at $1.03M in Q4 2022. 232 funds tracked by Wall St. Rank hold CNMD as of Q1 2023.

Brookfield Corp reported no remaining CONMED position as of Q1 2023 after selling out during the quarter.
Brookfield Corp sold 11,598 CONMED shares in Q1 2023, an estimated $1.03M.
Brookfield Corp first reported a position in CONMED in Q4 2022 and held it in 1 quarter.
Brookfield Corp's CONMED position peaked at $1.03M in Q4 2022.
232 funds tracked by Wall St. Rank held CONMED as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.